Drug intelligence / Profile preview

AdimFlu-W

Development stage: Phase 2
Lead developer: Adimmune
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AdimFlu-W is an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, developed by Adimmune Corporation. It is designed to provide immunity against influenza A (H5N1) by eliciting an immune response to the hemagglutinin protein of the virus. Each 0.5 mL dose contains 15 mcg of hemagglutinin from influenza A (A/Vietnam/1194/2004).

Brand names: AdimFlu-W
Other names: Pandemic Influenza Vaccine (H5N1)AdimFlu-W (H5N1)

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on AdimFlu-W.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdimFlu-W.

Explore the full profile